Last reviewed · How we verify

trimetaphan

unknown active

trimetaphan is a drug. It is currently in unknown development for Controlled Hypotension, Hypertensive Emergencies, Pulmonary edema.

At a glance

Generic nametrimetaphan
TargetNeuronal acetylcholine receptor subunit alpha-10, Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4
Therapeutic areaNeuroscience
Phaseunknown

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about trimetaphan

What is trimetaphan?

trimetaphan is a pharmaceutical drug, indicated for Controlled Hypotension, Hypertensive Emergencies, Pulmonary edema.

What is trimetaphan used for?

trimetaphan is indicated for Controlled Hypotension, Hypertensive Emergencies, Pulmonary edema.

What development phase is trimetaphan in?

trimetaphan is in unknown.

What does trimetaphan target?

trimetaphan targets Neuronal acetylcholine receptor subunit alpha-10, Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing